Overview

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Brexpiprazole